miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy

Clinical Cancer Research

Volumn 15, Issue 16, 2009, Pages 5060-5072

  Adam, Liana ^a   Zhong, Meng ^a   Choi, Woonyoung ^a   Qi, Wei ^a   Nicoloso, Milena ^a   Arora, Ameeta ^a   Calin, George ^a   Wang, Hua ^a   Siefker Radtke, Arlene ^a   McConkey, David ^a   Bar Eli, Menashe ^a   Dinney, Colin ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LUCIFERASE; MICRORNA; TRANSCRIPTION FACTOR ERRF1; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; UVOMORULIN;

3' UNTRANSLATED REGION; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER RESISTANCE; CELL MIGRATION; CELL TRANSFORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG TARGETING; EPITHELIUM CELL; HUMAN; HUMAN CELL; LENTIVIRINAE; MESENCHYME CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; RETROVIRUS; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL DEDIFFERENTIATION; DRUG RESISTANCE, NEOPLASM; EPITHELIUM; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESENCHYMAL STEM CELLS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 69349087756     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2245     Document Type: Article

References (43)

1. Dinney CP, McConkey DJ, Millikan RE, et al. Focus on bladder cancer. Cancer Cell 2004;6:111-116, review.
2. Dreicer R. Advanced bladder cancer: so many drugs, so little progress: what's wrong with this picture? Cancer 2008;113:1275-1277
3. Zhang X, Atala A, Godbey WT. Expressiontargeted gene therapy for the treatment of transitional cell carcinoma. Cancer Gene Ther 2008; 15:543-552
4. Agarwal PK, Black PC, McConkey DJ, Dinney CP. Emerging drugs for targeted therapy of bladder cancer. Expert Opin Emerg Drugs 2007;12: 435-448, review.
5. Blaveri E, Brewer JL, Roydasgupta R, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005;11:7012-7022 (Pubitemid 41428761)
6. Haber DA, Bell DW, Sordella R, et al. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harbor Symp Quant Biol 2005;70:419-426, review. (Pubitemid 44124897)
7. Blehm KN, Spiess PE, Bondaruk JE, et al. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res 2006;12:4671-4677
8. Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005;11:8686-8698 (Pubitemid 43005918)
9. Miyanaga A, Gemma A, Ando M, et al. Ecadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib. Oncol Rep 2008;19:377-383 (Pubitemid 351176097)
10. Shrader M, Pino MS, Brown G, et al. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther 2007;6: 277-285 (Pubitemid 46206692)
11. Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66:944-950 (Pubitemid 43165962)
12. Black PC, Brown GA, Inamoto T, et al. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008;14:1478-1486
13. Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005;65: 9455-9462 (Pubitemid 41508014)
14. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-715 (Pubitemid 351636299)
15. Pettitt J. The cadherin superfamily. WormBook 2005;:1-9, review.
16. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007;67:7972-7976
17. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601.
18. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008;283:14910-14914
19. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008;22: 894-907.
20. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005;123:631-640 (Pubitemid 41608466)
21. Gregory RI, Chendrimada TP, Shiekhattar R. MicroRNA biogenesis: isolation and characterization of the microprocessor complex. Methods Mol Biol 2006;342:33-47, review.
22. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-866, review.
23. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-269
24. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449:682-688 (Pubitemid 47552092)
25. Kassouf W, Dinney CP, Brown G, et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of gefitinib in bladder cancer cells. Cancer Res 2005;65:10524-10535 (Pubitemid 41748146)
26. Dinney CP, Fishbeck R, Singh RK, et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 1995;154:1532-1538
27. Wiley HS. Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res 2003;284: 78-88.
28. Sweeney C, Carraway KL III. Negative regulation of ErbB family receptor tyrosine kinases. Br J Cancer 2004;90:289-293 (Pubitemid 38250616)
29. Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 2005;1:2005.0008.
30. Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouysségur J. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J 1999;18:664-674 (Pubitemid 29057251)
31. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, et al. Differential endocytic routing of homoand hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 1998;17:3385-3397 (Pubitemid 28279512)
32. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 2002;156:843-854 (Pubitemid 34839867)
33. Fiorini M, Ballarò C, Sala G, Falcone G, Alemà S, Segatto O. Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control. Oncogene 2002;21:6530-6539 (Pubitemid 35155457)
34. Lafont JE, Talma S, Hopfgarten C, Murphy CL. Hypoxia promotes the differentiated human articular chondrocyte phenotype through SOX9-dependent and -independent pathways. J Biol Chem 2008;283:4778-4786
35. Zhang YW, Vande Woude GF. Mig-6, signal transduction, stress response and cancer. Cell Cycle 2007;6:507-513 (Pubitemid 46440419)
36. Makkinje A, Quinn DA, Chen A, et al. Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in the response to persistent stress. J Biol Chem 2000;275:17838-17847 (Pubitemid 30430836)
37. Anastasi S, Baietti MF, Frosi Y, Alemà S, Segatto O. The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFRca talytic activity. Oncogene 2007;26: 7833-7846 (Pubitemid 350261785)
38. Anastasi S, Fiorentino L, Fiorini M, et al. Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene 2003; 22:4221-4234 (Pubitemid 36876243)
39. Fiorentino L, Pertica C, Fiorini M, et al. Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol Cell Biol 2000;20:7735-7750 (Pubitemid 30736897)
40. Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 2007;450:741-744 (Pubitemid 350207680)
41. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-3237 (Pubitemid 47325606)
42. Wu W, O'Reilly MS, Langley RR, et al. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Mol Cancer Ther 2007;6:2652-2663 (Pubitemid 350058146)
43. Pece S, Gutkind JS. Signaling from E-cadherins to the MAPK pathway by the recruitment and activation of epidermal growth factor receptors upon cell-cell contact formation. J Biol Chem 2000;275:41227-41233 (Pubitemid 32054955)